
Results
17
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
17 companies
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$527.69
7D
0.5%
1Y
74.3%
Insmed
Market Cap: US$30.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$140.98
7D
-8.1%
1Y
97.9%
Ionis Pharmaceuticals
Market Cap: US$12.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$74.78
7D
-2.6%
1Y
157.6%
Alnylam Pharmaceuticals
Market Cap: US$41.2b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$308.43
7D
-9.1%
1Y
30.3%
Ascendis Pharma
Market Cap: US$15.2b
Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
ASND
US$240.29
7D
n/a
1Y
n/a
BridgeBio Pharma
Market Cap: US$14.9b
A biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BBIO
US$76.18
7D
-2.2%
1Y
122.9%
BeOne Medicines
Market Cap: US$35.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$312.31
7D
0.7%
1Y
23.6%
AbbVie
Market Cap: US$360.3b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$205.12
7D
-2.4%
1Y
18.0%
Jazz Pharmaceuticals
Market Cap: US$12.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$199.03
7D
-1.0%
1Y
92.5%
Eli Lilly
Market Cap: US$823.1b
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$903.02
7D
-2.1%
1Y
9.1%
Natera
Market Cap: US$29.4b
A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
NTRA
US$205.42
7D
-4.3%
1Y
42.0%
Viatris
Market Cap: US$17.3b
Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
VTRS
US$14.73
7D
5.9%
1Y
91.5%
Royalty Pharma
Market Cap: US$29.2b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$49.48
7D
1.4%
1Y
53.7%
Elanco Animal Health
Market Cap: US$11.8b
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN
US$22.61
7D
-6.2%
1Y
154.3%
Revvity
Market Cap: US$10.4b
Provides health sciences solutions, technologies, and services.
RVTY
US$94.27
7D
0.8%
1Y
2.1%
Waters
Market Cap: US$32.9b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$335.23
7D
1.3%
1Y
1.4%
BioMarin Pharmaceutical
Market Cap: US$10.6b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$54.62
7D
-1.5%
1Y
-11.2%